- LIVER TRANSPLANT REJECTION - PIPELINE BY REDHILL BIOPHARMA LTD, H1 2017
- LIVER TRANSPLANT REJECTION - PIPELINE BY NOVARTIS AG, H1 2017
The company' s pipeline products include oral combination therapy candidates for the treatment of helicobacter pylori infection, Crohn' s disease and multiple sclerosis; uPA inhibitor for the treatment of gastrointestinal and other solid tumor cancers; Hsp## inhibitor for the treatm
- LIVER TRANSPLANT REJECTION - PIPELINE BY DOMPE FARMACEUTICI SPA, H2 2017
- LIVER TRANSPLANT REJECTION - PIPELINE BY CONATUS PHARMACEUTICALS INC, H2 2017
The company' s commercial product portfolio consists of gastrointestinal therapeutics for acute enterocolitis and irritable bowel syndrome (IBS), and chronic diarrhea and loose stools.
- LIVER TRANSPLANTATION - PIPELINE BY REDHILL BIOPHARMA LTD., H1 2016
As of January 2011, Phase I/ II for gastrointestinal stromal tumor (GIST), chronic myelocytic leukemia (CML).
- LIVER TRANSPLANTATION - PIPELINE BY REDHILL BIOPHARMA LTD., H2 2015
It intends to acquire and develop late clinicalstage, proprietary drugs for the treatment of gastrointestinal and inflammatory conditions.
- Clinical Trial profile. 104 Trial Title
- Clinical Trial Profile Snapshots
Gastrointestinal Tolerability of Mycophenolate Mofetil (MMF, Cellcept) and Enteric-coated Mycophenolate Sodium (EC-MPS, Myfortic) in Maintenance Transplant Patients Treated with Calcineurin Inhibitors Gastrointestinal Tolerability of MMF vs EC-MPS in Maintenance Transplant Patients